Exact Sciences Corporation (NASDAQ:EXAS) Shares Fly 30% But Investors Aren't Buying For Growth
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Express News | Exact Sciences Corp : Piper Sandler Cuts Target Price to $75 From $80
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Exact Sciences (EXAS) and Fulcrum Therapeutics (FULC)
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
Scotiabank Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $70
